Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) Products under Development by Stage of Development | 7 | 1 |
| NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) Products under Development by Therapy Area | 8 | 1 |
| NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) Products under Development by Indication | 9 | 1 |
| NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) Products under Development by Companies | 12 | 2 |
| NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) Therapeutics Assessment | 14 | 4 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 1 |
| Assessment by Molecule Type | 17 | 1 |
| NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) Companies Involved in Therapeutics Development | 18 | 2 |
| GenKyoTex S.A. | 18 | 1 |
| Glucox Biotech AB | 19 | 1 |
| NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) Drug Profiles | 20 | 11 |
| GKT-136901 Drug Profile | 20 | 1 |
| GKT-831 Drug Profile | 21 | 3 |
| Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy Drug Profile | 24 | 1 |
| Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy Drug Profile | 25 | 1 |
| Small Molecule to Inhibit NOX-4 for Endothelial Dysfunction Drug Profile | 26 | 1 |
| Small Molecule to Inhibit NOX-4 for Heart Failure Drug Profile | 27 | 1 |
| Small Molecule to Inhibit NOX-4 for Type-2 Diabetes Drug Profile | 28 | 1 |
| Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke Drug Profile | 29 | 1 |
| Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke Drug Profile | 30 | 1 |
| NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) Dormant Projects | 31 | 1 |
| NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) Featured News &Press Releases | 32 | 10 |
| Nov 11, 2015: Genkyotex's GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis | 32 | 1 |
| Sep 09, 2015: Genkyotex Announces Top-Line Results of Phase 2 Clinical Program | 32 | 1 |
| Jul 30, 2015: Genkyotex's NOX1&4 Inhibitor Strategy in Liver Fibrosis Supported by New Preclinical Results | 33 | 1 |
| Nov 13, 2014: Genkyotex Completes Enrollment into Phase 2 Trial of NOX1&4 Inhibitor GKT137831 in Diabetic Nephropathy | 33 | 1 |
| Apr 10, 2014: Genkyotex s GKT137831 Found to Reverse Fibrosis and Improve Survival in a Model of Persistent Lung Fibrosis | 34 | 1 |
| Nov 11, 2013: Genkyotex NOX Inhibitor GKT137831 Successfully Shown to Halt Diabetic Kidney Disease | 35 | 1 |
| Nov 05, 2013: Genkyotex Initiates Multinational Phase II Study with First in Class NOX Inhibitor GKT137831 in Diabetic Nephropathy Patients | 36 | 1 |
| Oct 21, 2013: Genkyotex Collaborators Elucidate Role of NOX4 in Osteoporosis | 36 | 1 |
| Sep 09, 2013: Genkyotex Receives FDA IND Approval for Phase II Clinical Study with First in Class NOX Inhibitor GKT137831 | 37 | 1 |
| May 07, 2013: Genkyotex Collaborators Discover Role of NOX in Development of Atherosclerosis in Diabetic Mice | 38 | 1 |
| Nov 02, 2012: Genkyotex Presents Phase I Data On NOX Inhibitor GKT137831 At Kidney Week 2012 | 39 | 1 |
| Oct 15, 2012: Genkyotex Announces Presentation Of Data From Phase I Studies Of GKT137831 At Kidney Week 2012 | 39 | 1 |
| Aug 07, 2012: New Drug Successfully Halts Fibrosis In Animal Model Of Liver Disease, Study Reports | 40 | 1 |
| Jun 22, 2012: Genkyotex Announces Successful Phase Ia Data With GKT137831 | 40 | 1 |
| Oct 31, 2011: GenKyoTex Starts Phase I Trial With NOX Inhibitor GKT137831 | 41 | 1 |
| Appendix | 42 | 2 |
| Methodology | 42 | 1 |
| Coverage | 42 | 1 |
| Secondary Research | 42 | 1 |
| Primary Research | 42 | 1 |
| Expert Panel Validation | 42 | 1 |
| Contact Us | 42 | 1 |
| Disclaimer | 43 | 1 |
